New Opportunity: The Biomedical Innovations of Tomorrow - Research Report on PhotoMedex, Axiall Corp, Varian Medical Systems,

 New Opportunity: The Biomedical Innovations of Tomorrow - Research Report on
   PhotoMedex, Axiall Corp, Varian Medical Systems, Volcano Corporation and
                          Navidea Biopharmaceuticals

PR Newswire

NEW YORK, March 15, 2013

NEW YORK, March 15, 2013 /PRNewswire/ --

Today, Investors Alliance announced new research reports highlighting
PhotoMedex Inc (NASDAQ:PHMD), Axiall Corp (NYSE: AXLL), Varian Medical
Systems, Inc. (NYSE: VAR), Volcano Corporation (NASDAQ: VOLC) and Navidea
Biopharmaceuticals Inc. (NYSE: NAVB). Today's readers may access these reports
free of charge - including full price targets, industry analysis and analyst
ratings - via the links below.

PhotoMedex Inc Research Report

PhotoMedex Inc.'s merge with Radiancy has proven to be a great move as the
company reaped favorable results in its 2012 Q4. Revenues rose to $54.8
million or a whopping increase of 91%, translating to a gross profit of $43
million. Equipped with a fortified marketing platform and management schemes,
the global skin health solutions company is making great leaps ahead of the
competition. A huge chunk of the company's success is being attributed to its
ability to successfully integrate operations and culture, given that it is
operating in different countries of the world. PhotoMedex also introduced
several breakthrough products like Neova® and XTRAC®, which gradually won the
favor of dermatologists and patients experiencing skin problems such as
psoriasis. The Full Research Report on PhotoMedex Inc - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.investors-alliance.com/r/full_research_report/2c1b_PHMD]

--

Axiall Corp Research Report

Axiall Corporation, formerly Georgia Gulf Corporation, has just been given a
"buy" rating by Citigroup last Tuesday. In fact, many analysts are optimistic
that the company will achieve positive results, both in its business and
stocks performance. The predictions gave Axiall a challenge to exceed its
results during the last quarter. The company reported $0.92 earnings per share
for the quarter, beating the analysts' estimate. Consequently, Axiall raked in
revenues of $784.70, falling a few dollars short of analysts' estimates. The
result was still favorable enough to prompt the company to move towards it
goals the current year. On average, analysts and investors are hopeful that
Axiall will achieve $5.15/share for fiscal 2013. The Full Research Report on
Axiall Corp - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.Investors-Alliance.com/r/full_research_report/65e6_AXLL]

--

Varian Medical Systems, Inc. Research Report

Varian Medical Systems, Inc. further bolstered its rank as one of the world's
leading radiotherapy and radiosurgery innovators. The company recently
introduced digital X-ray image detectors that are portable, fast, capable of
generating high-quality images and usable around the world. This is good news
to medical practitioners and patients alike because majority of the said
devices require just minimal doses. Varian claimed that the detectors were
designed to enable accurate medical decisions while keeping X-ray dose to a
minimum. More than just the monetary return when the devices become widely
available, Varian is positive that the new technology will yield significant
benefits to patients worldwide. The Full Research Report on Varian Medical
Systems, Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.investors-alliance.com/r/full_research_report/f40b_VAR]

--

Volcano Corporation Research Report

Volcano Corporation continues to revolutionize the medical device industry by
introducing different types of technologies that make imaging and therapy
easier, simpler and a lot less invasive. The company participated in the
recent Barclays Global Healthcare Conference 2013 to discuss it recent
breakthroughs and new products. Medical device manufacturers and investors
attended the said forum, opening Volcano Corporation to more opportunities to
share their ideas with likeminded people. The Full Research Volcano
Corporation - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.investors-alliance.com/r/full_research_report/6ba1_VOLC]

--

Navidea Biopharmaceuticals Inc. Research Report

Navidea Biopharmaceuticals, Inc., a biomedical company that develops and sells
oncology products, is currently developing four radiopharmaceutical platforms.
These include Lymphoseek®, NAV4694, NAV5001 and RIGScan™, which are aimed at
identifying the sites and pathways of commonly undetectable disease for
improved and more accurate diagnosis, clinical recommendations and patient
care. Navidea is also planning to identify and partner with distributors in
other markets outside of the US. The Full Research Report on Navidea
Biopharmaceuticals, Inc. - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:
[http://www.investors-alliance.com/r/full_research_report/0b2f_NAVB]

--

Consider Investors Alliance

Tired of hearing about the latest, greatest trade opportunity... only to
realize that the ship has long sailed? You need a strong, informative
community in your arsenal. Join the group that has been consistently
identifying momentous situations as they develop - long before they become the
next top news on major financial networks.

Contact: Patricia Byers
Email: press@investors-alliance.com
Main: +1-480-745-7826

SOURCE Investors-Alliance